Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors Under Normal Clinical Practice

CompletedOBSERVATIONAL

Enrollment

321

Participants

Timeline

Start Date

March 10, 1999

Primary Completion Date

March 9, 2010

Study Completion Date

March 9, 2010

Conditions

Congenital Bleeding DisorderHaemophilia A With InhibitorsHaemophilia B With Inhibitors

Interventions

DRUG

eptacog alfa (activated)

Prescription of eptacog alpha at the discretion of the physician

Trial Locations (1)

Novo Nordisk Investigational Site, Tokyo